Bukowski, R.M., Eisen, T., Szczylik, C., et al. (2007) Final results of the randomized phase trial of Sorafenib in advanced renal cell carcinoma: Survival and biomarker analysis. Journal of Clinical Oncology, 25, 5023.

has been cited by the following article:

• TITLE: Metastatic sarcomatoid renal cell carcinoma to the mandible treated with Sorafenib

  AUTHORS: Kazuhiro Murakami, Kazuhiko Yamamoto, Kumiko Aoki, Ikuyo Fukumoto, Tsutomu Sugiura, Tadaaki Kirita

  KEYWORDS: Sarcomatoid Renal Cell Carcinoma; Oral Metastatic Lesion; Molecular Targeted Therapy; Sorafenib

  JOURNAL NAME: Open Journal of Stomatology, Vol.2 No.3, September 27, 2012

  ABSTRACT: A case of metastatic sarcomatoid renal cell carcinoma to the mandible treated with Sorafenib is reported. A 76-year-old man consulted us for hyposthesia of the right lower lip. Panorama X-ray film showed a ra-diolucent lesion in the right mandibular body. A diagnosis of metastatic tumor to the mandible from the left kidney was made after evaluation by computed tomography and positron emission tomography, which also revealed multiple bone metastases. After radiotherapy for mandibular and thoracic lesions, nephrectomy was performed. Histological diagnosis was sarcomatoid renal cell carcinoma. Interferon therapy was performed but was not effective; therefore, a molecular targeted drug, Sorafenib, was administered. Sorafenib effectively inhibited the growth of oral and other metastatic lesions for 10 months. Quality of life was relatively well maintained with tolerable adverse effects. The patient survived for as long as 2 years after appearance of the first symptom.